AtriCure, Inc. 10-Q Filing Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for AtriCure, Inc., a medical device company specializing in cardiac surgical ablation systems. The report covers the quarterly period ended September 30, 2009, and the nine-month period ended on the same date. The company operates as a single segment, selling primarily in the United States and internationally through direct sales and distributors.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 |
|---|---|---|
| Revenues | $13.28 million | $40.73 million |
| Gross Profit | $10.00 million (75.3% margin) | $31.40 million (77.1% margin) |
| Net Loss | $(4.70) million | $(14.10) million |
| Net Loss Per Share (Basic/Diluted) | $(0.32) | $(0.98) |
| Cash and Cash Equivalents | $10.57 million (as of Sep 30, 2009) | |
| Total Investments (Short & Long Term) | $5.82 million (as of Sep 30, 2009) | |
| Working Capital | $19.77 million | |
| Total Debt (Current + Long Term) | $5.30 million | |
| Operating Cash Flow (9 Months) | $0.33 million (provided by operations) |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 10.3% for the quarter and 5.7% for the nine-month period compared to 2008. The decline was driven primarily by a 14.0% drop in domestic sales, specifically in minimally invasive products. International sales grew 9.5% for the quarter and 18.1% for the nine-month period.
- Expense Reductions: Selling, general, and administrative (SG&A) expenses decreased significantly (20.8% for the quarter, 21.5% for nine months) due to headcount reductions in the sales force and reduced marketing/travel spending.
- Non-Recurring Charges:
- Goodwill Impairment: A full impairment charge of $6.81 million was recorded in the first quarter of 2009 due to a reduction in market capitalization.
- Settlement Reserve: A $3.77 million charge was recorded in the third quarter related to a tentative settlement with the U.S. Department of Justice (DOJ).
- Debt Restructuring: The company terminated its credit facility with National City Bank and entered a new $10.0 million facility with Silicon Valley Bank in May 2009, borrowing $6.5 million under a term loan.
Outlook, Risks, and Contingencies
- Legal Proceedings:
- DOJ Investigation: The company has reached a tentative settlement regarding an investigation into marketing practices and billing codes. A liability of $3.77 million has been recorded. The settlement terms are not yet finalized.
- Class Action Lawsuits: Two securities class action lawsuits are pending. A $2.0 million liability has been recorded for one case (with a corresponding insurance receivable), while the liability for the second case cannot be estimated.
- Qui Tam Complaint: A qui tam complaint related to the DOJ investigation was unsealed; the DOJ declined to intervene, but the relators may continue the litigation.
- Liquidity: Management believes current cash, investments, and the revolving credit facility (with $0.54 million availability) are sufficient to meet needs for the next 12 months. However, global economic turmoil and the costs associated with legal settlements remain risks.
- Product Pipeline: The company received CE Mark approval for the AtriClip System in Europe (launching Q4 2009) and plans a U.S. release in H1 2010.
- Debt Covenants: A loan modification agreement was executed in November 2009 to adjust financial covenants to exclude the impact of the DOJ settlement.
Investor Verification Checklist
- Verify the finalization status and payment terms of the tentative DOJ settlement ($3.77 million liability).
- Monitor the progress of the two pending securities class action lawsuits and the qui tam complaint.
- Assess the impact of the sales force reduction on future revenue growth, particularly in the domestic market.
- Review the adoption rates of new products (Cryo1 and AtriClip) to offset declines in legacy minimally invasive product sales.
- Confirm compliance with the amended financial covenants under the Silicon Valley Bank credit facility.